인간 EGFR/KRAS/BRAF/PIK3CA/ALK/ROS1 유전자 변이 감지 키트 시장 : 시장 예측(2026-2032년)

The Human EGFR/KRAS/BRAF/PIK3CA/ALK/ROS1 Gene Mutation Detection Kit Market is projected to grow by USD 491.12 million at a CAGR of 10.43% by 2032.

Human EGFR, KRAS, BRAF, PIK3CA, ALK, and ROS1 mutation detection kits support molecular characterization of tumors and help inform biomarker-guided clinical decision-making. Their relevance is strongest in oncology pathways where treatment selection, resistance assessment, and diagnostic confirmation depend on identifying actionable genomic alterations. Adoption is shaped by analytical performance, specimen quality, workflow integration, regulatory requirements, reimbursement, and access to trained laboratory personnel.

Transformative Shifts in Precision Oncology Diagnostics

The diagnostic landscape is shifting from single-gene testing toward multiplex and sequential testing strategies that improve tissue utilization and broaden biomarker coverage. Laboratories are also balancing tissue-based assays with liquid biopsy approaches, while emphasizing reproducibility, turnaround time, quality assurance, and compatibility with existing platforms. Companion-diagnostic alignment, decentralized testing, and clearer interpretation of complex variant results are becoming increasingly important as oncology care moves toward more individualized treatment pathways.

Artificial Intelligence Strengthens Interpretation and Workflow Efficiency

Artificial intelligence can improve this field by supporting image and signal interpretation, flagging quality-control anomalies, prioritizing variants, and helping laboratories manage workflow data. Its value depends on representative validation datasets, transparent performance measures, human oversight, cybersecurity, and compliance with applicable medical-device requirements. AI should augment-not replace-laboratory professionals, particularly when results are technically ambiguous or have significant treatment implications.

Regional Insights Across Global Diagnostic Systems

North America generally benefits from advanced molecular laboratories, established oncology networks, and structured biomarker testing pathways, although access and reimbursement can vary by jurisdiction. Europe combines strong research capacity with diverse national regulatory and funding environments. Asia-Pacific includes sophisticated testing ecosystems alongside rapidly expanding access needs, with infrastructure and workforce differences across markets. Latin America continues to face uneven availability of specialized testing and relies on referral networks in many settings. The Middle East is developing centralized and hospital-based molecular capabilities, while Africa's implementation is influenced by laboratory infrastructure, financing, specimen logistics, and specialist availability.

Group Insights Reveal Different Policy and Access Priorities

ASEAN economies show varied laboratory maturity and benefit from regional cooperation, shared training, and streamlined referral systems. BRICS members combine substantial scientific capabilities with pronounced differences in affordability, procurement, and geographic access. The European Union emphasizes harmonized quality, data governance, and cross-border diagnostic standards, while G7 systems generally prioritize evidence generation, interoperability, and clinical utility. GCC countries are investing in advanced healthcare infrastructure and centralized expertise. NATO members span diverse health systems, making resilient supply chains, common quality practices, and secure data exchange particularly relevant.

Country-Level Considerations for Implementation

Australia and Canada must address geographic dispersion and equitable access across centralized health services. Brazil, Mexico, and India face large and diverse patient populations, with referral capacity, affordability, and laboratory standardization remaining important considerations. China, Japan, and South Korea have strong clinical and research capabilities but differ in regulatory pathways, procurement structures, and adoption practices. France, Germany, Italy, Spain, and the United Kingdom operate within mature European oncology environments, with implementation influenced by national assessment, reimbursement, and laboratory governance. Russia's diagnostic environment is shaped by domestic capacity, procurement conditions, and access to specialized technologies. In the United States, broad laboratory capability coexists with variation in payer coverage, testing pathways, and clinical-site practices.

Action Priorities for Leaders in Molecular Diagnostics

Industry leaders should validate assays across relevant specimen types and clinically important variants, document analytical performance transparently, and design workflows that minimize tissue consumption and repeat testing. They should build partnerships with oncology networks and reference laboratories, invest in proficiency testing and workforce development, and prepare evidence that demonstrates clinical utility rather than technical performance alone. Regional strategies should account for regulatory differences, reimbursement realities, supply continuity, data protection, and equitable access. AI-enabled features should be introduced through controlled validation, monitoring, and clear accountability mechanisms.

Research Methodology for the Executive Summary

This executive summary uses the specified diagnostic category and required geographic groupings as its analytical scope. The assessment is structured around established considerations in molecular oncology diagnostics, including biomarker relevance, multiplex testing, laboratory workflow, regulatory oversight, reimbursement, infrastructure, quality management, and responsible AI use. Regional, group, and country observations are qualitative and comparative; no market estimates, shares, forecasts, or company-specific claims are included. Conclusions should be supplemented with current jurisdiction-level clinical guidelines, regulatory documents, reimbursement policies, and laboratory validation evidence before operational decisions are made.

Conclusion: Building Reliable, Equitable Biomarker Testing Pathways

Multiplex detection of EGFR, KRAS, BRAF, PIK3CA, ALK, and ROS1 alterations is an important component of precision oncology, but its impact depends on more than assay availability. Reliable implementation requires validated performance, integrated clinical workflows, skilled interpretation, sustainable quality systems, and equitable patient access. Organizations that combine technical rigor with regional adaptation and responsible use of artificial intelligence will be better positioned to support timely, clinically meaningful molecular decisions.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Human EGFR/KRAS/BRAF/PIK3CA/ALK/ROS1 Gene Mutation Detection Kit Market, by Technology

• 7.1. Introduction
• 7.2. Digital Pcr
• 7.3. Next Gen Sequencing
  • 7.3.1. Targeted Sequencing
  • 7.3.2. Whole Exome Sequencing
  • 7.3.3. Whole Genome Sequencing
• 7.4. Real Time Pcr
• 7.5. Sanger Sequencing

8. Human EGFR/KRAS/BRAF/PIK3CA/ALK/ROS1 Gene Mutation Detection Kit Market, by Cancer Type

• 8.1. Introduction
• 8.2. Breast Cancer
• 8.3. Colorectal Cancer
• 8.4. Lung Cancer
• 8.5. Melanoma

9. Human EGFR/KRAS/BRAF/PIK3CA/ALK/ROS1 Gene Mutation Detection Kit Market, by Sample Type

• 9.1. Introduction
• 9.2. Blood Plasma
• 9.3. Tissue

10. Human EGFR/KRAS/BRAF/PIK3CA/ALK/ROS1 Gene Mutation Detection Kit Market, by Product Type

• 10.1. Introduction
• 10.2. Instruments
• 10.3. Reagent Kits

11. Human EGFR/KRAS/BRAF/PIK3CA/ALK/ROS1 Gene Mutation Detection Kit Market, by End User

• 11.1. Introduction
• 11.2. Academic And Research Institutes
• 11.3. Diagnostic Laboratories
• 11.4. Hospitals And Clinics

12. Human EGFR/KRAS/BRAF/PIK3CA/ALK/ROS1 Gene Mutation Detection Kit Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Human EGFR/KRAS/BRAF/PIK3CA/ALK/ROS1 Gene Mutation Detection Kit Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Human EGFR/KRAS/BRAF/PIK3CA/ALK/ROS1 Gene Mutation Detection Kit Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories, Inc.
• 16.2. Agilent Technologies, Inc.
• 16.3. Amoy Diagnostics Co., Ltd.
• 16.4. Bio-Rad Laboratories, Inc.
• 16.5. Biocartis NV
• 16.6. bioMerieux SA
• 16.7. EntroGen, Inc.
• 16.8. Illumina, Inc.
• 16.9. Pillar Biosciences, Inc.
• 16.10. QIAGEN N.V.
• 16.11. Roche Holding AG
• 16.12. Sysmex Corporation
• 16.13. Thermo Fisher Scientific, Inc.

17. Key Experts